There are two things which Ocata have not been able to do: 1) Put a product on the market, the former by which their own admission in their filings is years away if ever. 2) Attract only one suitor up unti now who was willing to pay as much as $8.50 a share and who closed a deal with Ocata at this price. Those are indisputable facts.
Do billionaires become patients themselves sometimes? Do billionaire patients like the "current healthcare options" available to them? What could OCAT bring to a billionaire? What could OCAT bring to millions of patients in need? Is someone attempting to fool current shareholders about the true "future value" of OCAT?
Do competitors of OCAT have these abilities that OCAT has?
1) the ability to halt the progression of AMD and SMD in FDA/EMA approved clinical trials.
2) the ability to provide significant visual acuity improvement in FDA/EMA approved clinical trials.
3) the ability to dramatically reverse MS in rats studies
4) the ability to make scalable, universal blood and platelets
5) the ability to show remission in canine's with Crohn's Disease
6) the ability to preserve kidney function and extend the lifespan of mice with lupus
News 
Market Data 
Discover 
